Caplin Point Laboratories is a 100% export-oriented pharmaceutical company that makes sterile injectables and other dosage forms for the US and Latin American markets. It operates through a combination of B2B sales and its own-label US business, with a direct distribution network across Latin America that employs over 700 people. The company has 60 ANDAs approved or acquired, and is one of only three or four Indian firms with the capability to operate 16-17 injectable lines. Its economics are exceptional: FY26 EBITDA margin was 38-39% and PAT margin 27-28%, with Caplin Steriles (the US injectables unit) posting a 30% EBITDA margin in FY26 and 33% in Q4 FY26. These margins reflect a niche position where the company earns over 50% more per ANDA than the industry average.
The persistence of these economics rests on multiple barriers. Regulatory approvals take 14-15 months on average versus the industry's 20 months, and the company has a record of first-cycle approvals for complex products like emulsion injections. The Latin American distribution network, built over 20 years, gives it 41% shelf space in independent pharmacies in Central America, which it plans to raise to 57% with a new liquid manufacturing facility. The anti-fragile model of keeping six months of stock in subsidiary warehouses ensures supply reliability that large tender customers value. Additionally, the company has a strong balance sheet with INR 2,726 crores in liquid assets and zero leverage, allowing it to acquire ANDAs and fund capex without dilution. These are not commodity economics; they are built on qualification cycles, last-mile distribution, and a regulatory track record that takes years to replicate.
The inflection point is the current INR 510 crores of identified capex to be spent over the next 18-24 months, which will bring the total injectable lines to 17 for regulated markets, expand IV bag capacity three-fold, and complete the oncology API plant and the Mexico factory. By FY28-29, the company expects to have over 100 ANDAs approved or acquired, with the US own-label business likely to double from its FY27 target of INR 200 crores to roughly INR 400 crores, given the 30 products launched in FY26 and 15 more in FY27. Caplin Steriles is guided to grow 25-30% in FY27, and with the new lines coming online, that growth rate should persist into FY28. In Latin America, the Chile contract for 135 products worth $10 million over 18 months and the Mexico target of $4 million in the next two quarters, plus the new brand launches in Dominican Republic, Guatemala, and Nicaragua starting September 2026, will add meaningful revenue. The company expects margins to be maintained or inch up from current levels as the drag from non-breakeven API and Amaris Clinical segments stabilizes.
Management has consistently delivered on its promises. In November 2025, it committed to bringing the COL injectables project online by December, and by February 2026 it reported that Phase 3 lines were starting and that oncology exhibit batches were underway. The May 2026 call confirmed that 60 ANDAs are now in hand, with 10 approvals in the last four quarters and 15 ANDAs acquired in FY26. The guidance has been upgraded: from a 10-11% revenue growth expectation for nine months FY26 to a 25-30% growth target for Caplin Steriles in FY27, and a doubling of US own-label revenue. The company has also maintained its PAT margin guidance of 27-28%, and its actual results have beaten its own internal targets (PAT margin 28.5% in Q3 FY26). Capital allocation is disciplined: zero debt, INR 523 crores operating cash flow in FY26 (80% cash conversion), and a clear plan to spend the remaining ~INR 500 crores of capex without external funding.
The earnings path is clear: if CSL grows 25-30% in FY27 and the new injectable lines contribute from FY28, consolidated revenue could grow at a 20-25% CAGR over the next two years, with EBITDA margins staying above 38% and PAT margins in the 25-29% band. The key watchpoint is execution risk on the massive capacity expansion and regulatory approvals. Delays in commissioning the 17 lines or in ANDA approvals would push the growth timeline out. Also, customer concentration in the US own-label business (four large wholesalers) and the tariff situation on US generics are risks. But the company has a track record of delivering on commitments, and its strong cash position provides a buffer. The kill shot would be a significant slip in the timeline for the Phase-III plant or a regulatory setback in a major market, but based on the current evidence, the business is on track to become a top-tier injectable player with sustained high margins.
companyname: Caplin Point Laboratories Limited ticker: CAPLIPOINT sector: Pharmaceuticals Caplin Point Laboratories Limited is a 100% export-oriented Indian pharmaceutical company. It manufactures finished dosage forms - injectables, ophthalmic products, oral solids, liquid orals, ointments, suppositories, and more - and sells them through two distinct businesses: emerging markets (Latin America and Africa) where it owns its distribution networks, and regulated markets (US, Canada, Australia) r...
Read the full report →capex, margin expansion, regulatory approval, geographic expansion
FY27 Caplin Steriles revenue growth guided at 25-30% driven by new capacity and own-label expansion targeting INR 200 crores
Guidance upgradedGet valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Caplin Point Laboratories Limited and 4,900+ companies.
5-day free pass. No card required.